The neuroendocrine tumors (NETs) are more frequent during the last decades. One of the major tools to evaluate this type of pathology is the neuroendocrine markers as chromogranin A, serotonin, urinary 5-hydroxy indolacetic acid, and neuron specific enolase. They change related to the disease progression, regardless therapy. Some of the drugs that are used for NETs as somatostatin analogs (for example octreotide) might interfere with glucose metabolism. Objectives. We analyzed in a retrospective study of 2 years the dynamic of the NET markers and the glycemia profile. Material and Methods. All the patients had at least one assay per year. Results. 9 patients were included (5 women and 4 men), with a mean age of 57.33 years. They were treated before the study with octreotide for 18 +/- 14.69 months. The dose of octreotide varied from 20 to 50 mg, monthly. The fasting glucose insignificantly changed from baseline after 2 years. No new case of diabetes was registered. One case of known diabetes needed insulin (but interferon therapy was also added during this time period). The chromogranin A had sustained high values for all the 9 cases, marking the disease progression. The neuron specific enolase significantly increased, and the serum serotonin as well as the 5HIIA was much higher in 2 cases with aggressive carcinoid symptoms. Conclusion. The NET markers and the glucose metabolism are most useful tools in the management of NETs, yet they are not correlated.
Keywords
- chromogranin A
- neuroendocrine tumor
- serotonin
Cuvinte cheie
- cromogranina A
- tumora neuroendocrina
- serotonina
Effects of nitroglycerin combined with continuous regional arterial infusion on severe acute pancreatitis, triglyceride, inflammatory factors and prognosis MMP-2 and MMP-9 gene polymorphisms and risk of head and neck carcinomas Proposal of a prediction model for prognosis of patients with acute myocardial infarction after percutaneous coronary intervention based on galectin-3 and soluble growth stimulating expressed gene 2 levels Crinum latifolium extract inhibits lipopolysaccharide-induced inflammation in human macrophages Approaching Risk Management in Medical Laboratories Non-inhibitory effects of the potent antioxidant C-phycocyanin fromPlectonema sp. on thein vitro glycation reactionAssociations of serum expressions of miR-499 and sex determining region Y-box 6 with prognosis of acute myocardial infarction patients Matrix-assisted Laser Desorption Ionization–Time of Flight Mass Spectrometry (MALDI-TOF MS) for subgingival bacteriome identification in a group of treated periodontitis patients: a case series Clinical significance of serum HMGB1 in COPD and correlation with severity of airflow restriction and immune function Snapshot of resistance and virulence features in ESCAPE strains frequently isolated from surgical wound infections in a Romanian hospital